Eli Lilly Earnings Preview (August 5): A $13 Billion Obesity Quarter and the First Oral Face-Off With Novo

TL;DR

• Eli Lilly reports Q2 2026 results Wednesday, August 5, before the open, thirty minutes of tape away from rival Novo Nordisk's very different morning.
• Consensus sees revenue of roughly $20.3 to $20.7 billion, up about 30% from $15.56 billion a year ago. The quarterly EPS consensus is unusually scattered, anywhere from $6.06 to $6.71 depending on the provider, so treat any single EPS "beat/miss" headline tomorrow with suspicion.
• The quarter is really two lines: Mounjaro plus Zepbound, which consensus puts above $13 billion combined, and the first meaningful launch quarter of Foundayo (orforglipron), the oral GLP-1, against Novo's oral Wegovy.
• The full-year guide is the bar: $82.0-85.0 billion of revenue and $35.50-37.00 of EPS, raised in April after a Q1 blowout ($19.80 billion, $8.55). After a beat-and-raise Q1, the debate is how much the ranges move, not whether the quarter beats.
• The stock closed Monday at $1,121.36, down 2.39%, at a market cap around $1.04 trillion, with options pricing roughly a 7% move.

When Does Eli Lilly Report Earnings?

The short answer: Wednesday August 5, before the market opens. It lands on the healthcare morning of the busiest week of the quarter, alongside Novo Nordisk, Disney and Uber.

The Board

Two lines decide the print: the incretin franchise, and the oral launch ramp.

The $13 Billion Franchise Question

Consensus puts Mounjaro and Zepbound combined above $13 billion for the quarter, with Morgan Stanley modelling $4.5 billion of Mounjaro outside the US alone. That franchise is the entire growth story: revenue up ~30% while the rest of pharma grinds out single digits. The known drag is pricing: the year-ago quarter already showed 6% US price erosion on the incretin lines, and net-pricing commentary will decide whether a revenue beat translates into margin.

A warning on the bottom line: the quarterly EPS consensus is genuinely contested across providers ($6.06 to $6.71), likely a GAAP-versus-adjusted and one-off-charges muddle. The revenue line and the full-year guide are the clean scoreboard; we would ignore tomorrow's inevitable "EPS beat by X%" headlines entirely.

Foundayo vs Oral Wegovy: The New Front

The FDA approved Foundayo (orforglipron), Lilly's oral GLP-1 for obesity, alongside the April results. This is its first meaningful launch quarter, and it lands two days after Novo disclosed its own oral Wegovy did DKK 2.26 billion in Q1, roughly double what analysts modelled. The oral market is where the next leg of the obesity trade gets decided, because pills scale where injectable supply chains and needle-averse patients do not. Any prescription-trend or launch-trajectory number for Foundayo is worth more than the headline EPS.

The Guide Is the Trade

In April, Lilly raised the full year to $82-85 billion of revenue and $35.50-37.00 of EPS after Q1 printed $19.80 billion and $8.55. The street's real question on Wednesday is the size of the next raise. The stock has been sold into the print (down about 4.5% in the run-up, including Monday's 2.39% drop to $1,121.36), which resets the bar somewhat: a hold-the-range quarter probably reads as a disappointment, but not a catastrophic one, against a tape that has already taken profits.

The Options Angle

Options price roughly a 7% move (quoted between 6.9% and 7.4% across providers), about $76 billion of market value in play on a $1.04 trillion company.

There is also a practical constraint most readers hit before any Greek does: at $1,121 a share, one options contract controls about $112,000 of stock. Cash-secured puts and covered calls on LLY are simply out of reach for most retail accounts, and fractional options do not exist. That pushes the realistic menu to defined-risk spreads or shares.

• No pre-print position. A 7% implied on a genuinely two-sided setup (franchise beat vs pricing erosion, raise vs hold) with a contested EPS consensus is a coin flip at premium prices.
• The post-print entry is the play if the raise comes: a lifted full-year range with Foundayo tracking is the confirmation to own with shares or call spreads, sized to the $112k-per-contract reality.

Trade log

#	Stance	Structure	Strikes and expiry	Cost or credit	Spot at writing	Implied move	Breakeven
1	Pass	Any pre-print options position	Aug expiries	Not sourced	$1,121.36, Aug 3 close	~7% (6.9-7.4% quoted)	n/a; pass scored against the realised move
2	Conditional	Post-print long (shares or defined-risk call spread) if FY guidance is raised	Struck off the Aug 5 open reaction	Struck off the Aug 5 post-print price	To be struck Aug 5	n/a	Scored against the post-print entry if triggered

The One-Line Read

Lilly reports a quarter the street already believes in, which is exactly the problem: with revenue growing 30%, a $13 billion obesity franchise and a guide raised once already, the only cheap surprise left is the size of the next raise and the speed of the Foundayo ramp, and the sold-off tape into Wednesday says the market wants proof before it pays up again.